Chronic administration of nano-sized PAMAM dendrimers in vivo inhibits EGFR-ERK1/2-ROCK signaling pathway and attenuate diabetes-induced vascular remodeling and dysfunction

This study showed chronic in vivo administration of PAMAM dendrimers in an animal model of diabetes inhibited EGFR-ERK1/2-ROCK signaling and improved diabetes-induced vascular remodeling and dysfunction in a dose, generation (G6 > G5) and surface chemistry-dependent manner (cationic> anionic> neutral). Thus, naked PAMAM dendrimers have the propensity to modulate key (e.g. EGFR) cell signaling cascades with associated pharmacological consequences in vivo that are dependent on their physicochemical properties. PAMAMs, alone or in combination with vasculoprotective agents, might therefore have a beneficial role in the potential treatment of diabetes-induced vascular complications.
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research